|Approvals/Requirements Satisfied by eRADIMAGING Courses|
|~ ASRT approval for ARRT Category A credit||~ MDCB approval by the Medical Dosimetrist Certification (Selected Courses)|
|~ ARMRIT accepted (All MRI Courses)||~ CAMRT and Sonography Canada recognize the ASRT approval (All Courses)|
|~ ARDMS accepted (All Courses)||~ Florida approval for all courses 1 credit or more|
|~ NMTCB accepted (All Courses)||~ California CE requirements met for all radiography courses|
|~ All Courses eligible of international radiographers' CPD requirements||~ All Courses available for RRAs|
|~ ASRT and MDCB are approved continuing education providers of ARRT and all courses are accepted by ARRT|
Parkinson Disease: An Overview of the Use of Nuclear Medicine for Central Nervous System Imaging
Mark P. Bowes, PhD
*Medical Writer, Portland, Oregon.
Address correspondence to: Mark P. Bowes, PhD, Medical Writer, 7135 SE 18th Avenue, Portland, OR 97202. E-mail: email@example.com.
Disclosure Statement: Dr Bowes reports having no financial or advisory relationships with corporate organizations related to this activity.
Parkinson disease (PD) is a progressive neurologic disorder that is characterized by resting tremor, slowed movement, rigidity, and postural instability. PD is also associated with a variety of nonmotor symptoms, including diminished sense of smell, abnormalities of the autonomic nervous system, impaired cognition, and depression. The symptoms of PD develop as a result of degeneration of neurons that originate in a portion of the midbrain known as the substantia nigra. These cells project to another region of the brain (the striatum) where they release the neurotransmitter dopamine. Although not curable, PD is treatable using a variety of medications that increase dopamine synthesis and release within the brain. PD may also be treated using surgery and other nonpharmacologic approaches. Because of the significant degree of overlap between the symptoms of PD and those of other motor disorders, it can be challenging to identify patients with PD, especially those with early disease. Routine neuroimaging approaches such as magnetic resonance imaging and computed tomography often fail to identify the subtle neurologic changes associated with PD. The US Food and Drug Administration recently approved the single-photon emission computed tomography ligand 123I-ioflupane for the assessment of dopamine function in patients with suspected PD. Several other radioligands are used in research settings and may also be helpful in identifying patients with PD. This article provides an overview of PD evaluation and treatment, including the typical clinical presentation, pathophysiology, pharmacologic and nonpharmacologic treatment approaches, assessment of brain dopamine activity using single-photon emission computed tomography, and other imaging methods that may also be useful in PD research, diagnosis, and treatment.
Full Course Content available to active members of eRADIMAGING.com
* This sample course is for reference purposes only. It is not currently available for earning CE credits. To earn ARRT CE credits please subscribe to eRADIMAGING where you will see a complete listing of all active and eligible CE courses.